- $289.46bn
- $331.15bn
- $56.33bn
Factbox: Major drugmakers turn to China for licensing deals
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen (updated)
Novartis strikes about $7.8 billion mRNA deal with China's Abogen
Brief: Abogen Announces Licensing And Option Agreement With Novartis
Swiss stocks - Factors to watch on September 24
Novartis defeats drug-purchaser lawsuit over delay of Entresto generics
Live Markets: RBC says AI weakness appears to be fueling biotech rally
Amgen's autoimmune drug succeeds in late-stage trial (updated)
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
European drugmakers call for faster trials, more spending to compete with US, China
Corrected: Amgen's autoimmune drug succeeds in late-stage trial
Big Pharma growth malady has a risky cure
Brief: Novartis Says CHMP Of European Medicines Agency (EMA) Adopted Positive Opinion Recommending Marketing Authorization For Cosentyx
Anthropic quietly sets up biology lab as it ramps AI drug program
Anthropic quietly sets up biology lab as it ramps AI drug program
India's Zydus Lifesciences to benefit from Novartis dropping rival ALS drug, says Bernstein
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Swiss stocks - Factors to watch on September 17
Novartis halts ALS drug development after mid-stage trial failure (updated)